Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

3 terminated/withdrawn out of 21 trials

Success Rate

76.9%

-9.7% vs industry average

Late-Stage Pipeline

5%

1 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
12(57.1%)
Phase 2
8(38.1%)
Phase 4
1(4.8%)
21Total
Phase 1(12)
Phase 2(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT05913388Phase 2Active Not Recruiting

GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT03247712Phase 1Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer

Role: collaborator

NCT03336606Phase 1Completed

Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma

Role: collaborator

NCT05349890Phase 1Active Not Recruiting

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Role: collaborator

NCT04061980Phase 2Active Not Recruiting

Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer

Role: collaborator

NCT04938609Phase 2Active Not Recruiting

Neoadjuvant Immunoradiotherapy in Head & Neck Cancer (NIRT 2-HNC)

Role: collaborator

NCT02422381Phase 1Active Not Recruiting

MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC)

Role: collaborator

NCT04364048Phase 2Terminated

Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer

Role: collaborator

NCT00554515Phase 2Completed

The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma

Role: collaborator

NCT04987996Phase 2Withdrawn

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

Role: collaborator

NCT04334967Phase 4Suspended

Hydroxychloroquine in Patients With Newly Diagnosed COVID-19 Compared to Standard of Care

Role: collaborator

NCT01862900Phase 1Completed

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions

Role: collaborator

NCT02117362Phase 1Completed

Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma

Role: collaborator

NCT02234921Phase 1Completed

Pilot Study of DRibble Vaccine for Prostate Cancer Patients

Role: collaborator

NCT01342224Phase 1Completed

Immunochemoradiotherapy in Patients With Pancreatic Cancer

Role: collaborator

NCT01909752Phase 2Completed

Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer

Role: collaborator

NCT01700400Phase 1Completed

Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer

Role: collaborator

NCT00091143Phase 1Completed

Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma

Role: lead

NCT00003184Phase 1Completed

Vaccine Therapy in Treating Women With Metastatic Breast Cancer

Role: lead

NCT00232206Phase 2Terminated

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer

Role: collaborator